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Three different myelin proteins, Nogo, MAG, and
OMgp, inhibit regenerating axons after CNS injury.
New work reveals that they all share a common
receptor and that blockade of this receptor promotes
CNS repair and functional recovery.
Unlike peripheral nervous system (PNS) axons, severed
central nervous system (CNS) axons are unable to
regenerate. Why do CNS and PNS axons differ so dra-
matically in their regenerative abilities? Differences in
CNS and PNS glial cells appear to be crucial, as some
CNS axons are able to regenerate through a peripheral
nerve graft [1]. Axons are tightly wrapped by myelin
membrane produced by oligodendrocytes in the CNS
and Schwann cells in the PNS. Following axonal injury
in the PNS, myelin is rapidly cleared by macrophages
as the axons degenerate in a process known as
Wallerian degeneration. In contrast, myelin is cleared
much more slowly after CNS injury. This difference
suggests that CNS myelin strongly inhibits regenerat-
ing axons, a possibility that was directly confirmed 
in elegant experiments by Martin Schwab and his
colleagues [2].
An important first step towards identifying myelin
inhibitors of axon regeneration was taken many years
ago with the development of an anti-CNS myelin mono-
clonal antibody, IN-1, which promotes CNS regenera-
tion and a limited degree of functional recovery in
animal models [2]. Only in the last few years, however,
have researchers begun to elucidate the key inhibitors
and their receptors, uncovering a few surprises along
the way. The target of the IN-1 antibody turned out to
be Nogo, a reticulon homolog with three isoforms:
Nogo-A is expressed primarily in oligodendrocytes,
and the other two isoforms are more widely distrib-
uted ([reviewed in [3]). Interestingly, Nogo-A has two
separate domains that can inhibit growing axons: the
amino-terminal portion (Amino-Nogo), which is unique
to Nogo-A, and a 66 amino acid peptide (Nogo-66)
located between the two transmembrane regions,
which is common to all isoforms.
How does Nogo inhibit regenerating axons? The
functional receptor for Nogo-66, NgR, is a 473 amino
acid protein with an attached glycosylphosphatidyli-
nositol (GPI) lipid. This GPI linkage serves to anchor
the protein to the outer surface of the cell membrane,
where it can interact with its ligand. Binding studies
and the effects of ectopic expression both confirmed
that this protein is the functional receptor for Nogo-66
[4]. The expression patterns of Nogo and NgR are
consistent with the interactions of these proteins at
points of contact between axons and myelin, as well as
at synapses [5]. It is unlikely, however, that NgR works
alone: its lack of a transmembrane region implies the
presence of an as yet unidentified transmembrane co-
receptor that transduces the inhibitory signal.
These new findings have already led to efforts to
develop drugs that enhance CNS regeneration. By ana-
lyzing small peptide fragments of Nogo-66, Strittmatter
and colleagues [6] found that, although residues 1–31
of Nogo-66 bind with high affinity to NgR, only a
peptide containing residues 31–55 inhibits axon out-
growth. On the basis of these results, they developed 
a competitive antagonist peptide, termed NEP1-40 
for ‘Nogo extracellular peptide residues 1–40’, which
specifically blocks Nogo-66, but not Amino-Nogo,
activity [6]. The delivery of NEP1-40 into an injured rat
spinal cord produces significant axon regrowth and 
a modest but noteworthy promotion of locomotor
recovery. This finding supports the view that NgR plays
an important role in CNS regenerative failure and is an
encouraging target for new therapeutics.
While Nogo has attracted much of the spotlight of
late, additional inhibitory myelin proteins are known.
One of these, myelin-associated glycoprotein (MAG),
shares with Nogo the interesting property that it inhibits
postnatal and adult, but not embryonic, neurons. MAG
binds to a sialic acid-bearing glycosphingolipid called
ganglioside GT1b and closely related gangliosides on
the neuronal surface. This ganglioside has been sus-
pected of helping to form a MAG receptor, because
clustering of GT1b by antibody complexes is sufficient
to inhibit neurite outgrowth by activating a Rho kinase
[7,8], but it has been unclear how a ganglioside could
help to transmit a signal across the plasma membrane.
Unexpectedly, the ganglioside GT1b turns out to asso-
ciate with the neurotrophin receptor p75 to form a MAG
receptor complex which transmits an inhibitory signal
via the small GTPase Rho [9]. As no inhibitory effect of
MAG is seen in the absence of p75, this complex
appears to be necessary and sufficient to mediate
MAG’s inhibitory effects.
In striking contrast to this report, a mutant MAG that
is unable to bind to gangliosides still inhibits neurite
outgrowth when expressed on Schwann cells, implying
the presence of an additional MAG receptor [10].
Intriguing new studies have revealed that the Nogo-66
receptor NgR fits the bill and, moreover, is itself
necessary and sufficient to mediate MAG’s inhibitory
actions [11,12]. These latest findings show that MAG
binding to NgR is independent of GT1b, that dominant-
negative forms of NgR block MAG activity, and that
NgR expression confers both MAG and Nogo-66
responsiveness on embryonic neurons. Importantly,
however, the NgR antagonist peptide NEP1-40 does
not interfere with MAG’s inhibitory activity [12], sug-
gesting that additional functional recovery may be
achieved by improved antagonists.
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How can GT1b-p75 and NgR each be necessary and
sufficient to mediate MAG’s inhibitory effects? The res-
olution of these seemingly conflicting reports may lie in
the propensity of both GPI-anchored proteins and gan-
gliosides to partition into cholesterol-rich microdomains
of the cell membrane known as lipid rafts. These are
gel-like collections of particular lipids and proteins that
float like tiny rafts in the more fluid surrounding mem-
brane. These microdomains can promote signaling by
clustering specific proteins together [13]. One possibil-
ity is that NgR and GT1b share the ability to cluster and
activate the same raft-associated signal transduction
apparatus, perhaps p75. Therefore, it will be interesting
to see whether Nogo-A directly or indirectly interacts
with GT1b and p75, whether inhibition by Nogo-66
requires p75, and whether antibody-mediated cluster-
ing of GT1b can still inhibit axon outgrowth in neurons
that lack NgR.
Are MAG and Nogo the only inhibitory proteins
found in myelin? Recognizing that the myelin sheath is
enriched in GPI-anchored proteins [14], Wang and col-
leagues [15] searched for GPI-linked proteins from
myelin that might be regeneration inhibitors. They
enzymatically released all GPI-anchored proteins from
purified myelin and found that this fraction contained
inhibitory activity. From its molecular weight, they
inferred that this activity is oligodendrocyte-myelin
glycoprotein (OMgp), a known myelin protein initially
isolated from human white matter, and then confirmed
that recombinant OMgp is in fact a potent neurite
inhibitor. Interestingly, like Nogo, OMgp is also made
by neurons [16]. Expression cloning revealed that the
binding partner of OMgp is none other than NgR, the
same receptor responsible for mediating the inhibitory
action of Nogo-66 and MAG. Ectopic NgR expression
confers OMgp sensitivity on embryonic neurons.
Nogo-66 and OMgp have similar affinities for NgR,
bind to overlapping regions, and compete for binding
[15]. So, remarkably, three very different myelin pro-
teins inhibit axon regeneration through a common
receptor, NgR (Figure 1).
A considerable amount of work remains to ascertain
the importance of these recent findings in injury
models. Continuing gene knockout studies in mice
should help to clarify the relative roles of Nogo, OMgp
and MAG in the blockade of axon outgrowth, as well
as their normal roles in development. Similarly, NgR-
deficient mice will allow assessment of myelin’s
contribution to regenerative failure, as well as the ther-
apeutic potential of disrupting this shared receptor.
While these new advances clearly make NgR a very
inviting target, there is plenty of evidence that myelin
inhibitors are only one of several obstacles that regen-
erating CNS axons face. They must also overcome
growth inhibitors produced by other glial cells called
astrocytes, as well as a lack of appropriate substrates
and trophic factors. Furthermore, recent studies have
shown that CNS neurons undergo apparently irre-
versible changes as the CNS matures that limit their
intrinsic regenerative ability [17]. Despite these imped-
iments, the success of NEP1-40 at promoting axon
growth and functional recovery gives good reason for
optimism. The development and testing of the next
generation of NgR antagonists, screened for the ability
to block the inhibitory activity of Nogo, MAG and
OMgp, will provide important insight into myelin’s role
in blocking regeneration and may, with a little luck,
even prove to be useful clinically.
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Figure 1. NgR is the shared receptor of three myelin-
associated inhibitors of axon growth.
The myelin proteins Nogo, OMgp and MAG block the regener-
ation of axons. All three inhibit axon outgrowth by binding to
the axonal GPI-anchored Nogo-66 receptor, NgR. MAG also
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yet-unknown transmembrane signal transducer, which may 
be the neurotrophin receptor p75. The antagonist peptide
NEP1–40, derived from the first 40 residues of Nogo-66, blocks
inhibition by Nogo-66 but not MAG (with OMgp yet to be
tested). NEP1–40 promotes recovery in a spinal cord injury
model, inspiring hope for future drugs that more completely
block the activation of NgR or its transducer.
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